Given that the anti-CCL5 strategy could only lead to a moderate therapeutic effect against colon cancer, we next sought to evaluate the potential of CCL5 blockade administered in combination with an anti-PDGFRβ strategy. The gene discussed is PDGFRB; the disease is malignant colon neoplasm.